In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols

Seminars in Surgical Oncology

Volumn 14, Issue 3, 1998, Pages 189-201

  Link, Karl Heinz ^a   Leder, Gerd ^a   Pillasch, Jürgen ^a   Butzer, Urwe ^a   Staib, Ludger ^a   Kornmann, Marko ^a   Bruckner, Uwe ^a   Beger, Hans Günther ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Antineoplastic agents; Cisplatin; Cultured tumor cells; Doxorubicin; Drug dose response relationship; Epirubicin; Flourodeokyuridine; Fluorouracil; Hepatic artery; HT29 cells; Intra arterial infusions; Intraperitoneal injections; Mitomycin C; Mitoxantrone; Regional perfusion; Therapeutic chemoembolisation

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLOXURIDINE; FLUOROURACIL; MITOMYCIN C; MITOXANTRONE;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CARCINOMA; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; LIVER PERFUSION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031895477     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199804/05)14:3<189::AID-SSU2>3.0.CO;2-4     Document Type: Article

References (69)

1. Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases [comment in: Lancet 1995; 345(8945):328-329]. Lancet 1994;344(8932):1255-1260.
2. Hagiwara A, Takahashi T, Kojima O, et al: Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer [comment in: Lancet 1992;339(8809):1608]. Lancet 1992; 339(8794):629-631.
3. Fujimoto S, Shrestha RD, Kokubun M, et al: Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg 1990;212:592-596.
4. Vetter D, Wenger JJ, Bergier JM, et al: Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 1991;13:427-433.
5. Anonymous: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. [comment in: J Natl Cancer Inst 1996;88:223-224]. J Natl Cancer Inst 1996;88:252-258.
6. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984;2:498-504.
7. Link KH, Gisa C, Muhrer KH, et al: Immunereactivity of colorectal carcinoma cell line NMG 64/84 in the electropheresis mobility test (EMT) [Abstract]. J Cancer Res Clin Oncol 1987;113:S43.
8. Link KH, Aigner KR, Peschau K, et al: Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells. Cancer Chemother Pharmacol 1988;22:58-62.
9. Schroy PC, Cohen A, Winawer SJ, Friedman EA: Effects of FUdR on primary-cultured colon carcinomas metastatic to the liver. J Surg Oncol 1990;45:217-223.
10. Link KH, Aigner KR, Kuehn W, et al: Prospective correlative chemosensitivity testing in high-dose intra-arterial chemotherapy for liver metastases. Cancer Res 1986;46:4837-4848.
11. Link KH, Kreuser ED, Safi F. et al: [The status of 5-FU and folinic acid (FA, Rescuvolin®) in the treatment concept of nonresectable colorectal liver matastases]. Tumordiagn Ther 1993;14:224-231. (Ger).
12. Link K: [Chemosensitivity tests for optimizing the regional chemotherapy of solid tumors. Basis research and clinical application]. [PhD Thesis] Ulm, Germany: University of Ulm, 1993. (Ger).
13. Link KH, Hepp G, Butzer U, et al: Rationales for intraperitoneal chemotherapy: chemosensitivity testing and pharmacokinetic considerations - clinical experience with intraperitoneal chemotherapy. Acta Chir Austriaca 1995;27:95-100.
14. Roper PR, Drewinko B: Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res 1976;36(7 Pt 1):2182-2188.
15. Takemoto T: [A comparative study of chemosensitivity tests in vitro for AUC-dependent drugs focusing on the usefulness of MTT assay with drug washout and additional incubation (M-MTT)]. Nippon Ika Daigaku Zasshi - J Nippon Med School 1993;60:156-164. (Jpn).
16. Hill BT: Use of continuous human tumour cell lines to evaluate drugs by clonogenic assay. In Dendy PP, Hill BT (eds): "Human tumour drug sensitivity testing in vitro: techniques and clinical applications". London: Academic Press; 1983. p. 129-146.
17. Daly JM, Kemeny N: Therapy of colorectal hepatic metastases. In "important advances in oncology 1986." Philadelphia: Lippincott; 1986. p. 251-268.
18. Ardalan B, Chua L, Tian EM, Reddy R, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. [comment in: J Clin Oncol 1993;11:384; J Clin Oncol 1993;11:1433-1434; J Clin Oncol 1994;12:875-876]. J Clin Oncol 1991;9:625-630.
19. Hildebrand-Zanki SU, Kern DH: A new bioassay for in vitro drug stability. In Salmon SE, Trent JM (eds): "Human tumor cloning." Orlando: Grune & Stratton; 1984. p. 451-458.
20. Bosanquet A: Stability of solutions of antinoplastic agents during preparation and storage for in vitro assays: general considerations, the nitrosureas and alkylating agents. Cancer Chemother Pharmaca 1985;14:83-95.
21. Karakousis CP, Kanter PM, Lopez R, et al: Modes of regional chemotherapy. J Surg Res 1979;26:134-141.
22. Taguchi T, Ogawa N, Bunke B, Nilsson B: The use of degradable starch microspheres (Spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumours - results of a phase III clinical trial. Reg Cancer Treat 1992;4:161-165.
23. Jaffe N, Raymond K, Ayala A, et al: Analysis of the efficacy of intra-arterial cis-diamminedichloroplatinum-II and high-dose methotrexate with citrovorum factor rescue in the treatment of primary osteosarcoma. Reg Cancer Treat 1989;2:157-163.
24. Jakowatz JG, Ginn GE, Snyder LM, et al: Increased cisplatin tissue levels with prolonged arterial infusion in the rat. Cancer 1991;67:2828-2832.
25. Civalleri D, Esposito M, Fulco RA, et al: Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administered with and without starch microspheres in patients with liver metastases. Cancer 1991;68:988-994.
26. Löffler T, Aigner KR, Hausamen TU: Cisplatin, mitomycin and 5-FU tissue concentrations in hepatic metastases after intra-arterial chemotherapy alone and with use of starch-microsheperes [Abstract]. Proceedings of the American Association of Cancer Research (AACR) 1985;26:156.
27. Wile AG, Kar R, Cohen RA, et al: The pharmacokinetics of cisplatin in experimental regional chemotherapy. Cancer 1987;59:695-700.
28. Higashihara J, Berens ME, Collins LA, et al: Combined antiproliferative activity of 5-fluorouracil and mitomycin-C against primary human ovarian tumors and cell lines in a clonogenic assay. Gynecol Oncol 1993;48:171-179.
29. De Bruijn EA, Slee PH, Kuppen PJ, et al: The importance of exposure time in regional chemotherapy: mitomycin C and fluoropyrimidines. Contr Oncol 1988;29:43-48.
30. Taguchi T: Intraarterial chemotherapy combined wth mitomycin C and degradable starch mircrospheres for unresectable metastatic liver cancer. In Taguchi T, Aigner KR (eds): "Mitomycin C in cancer chemotherapy today". Tokyo: Excerpta Medica; 1991. p. 149-151.
31. Starkhammar H: How to improve regional chemotherapy by influencing tumor blood flow - an overview. Eur J Surg 1991;Suppl 561:31-34.
32. Lokich J, Perri J, Fine N, et al: Mitomycin C: phase I study of a constant infusion ambulatory treatment schedule. Am J Clin Oncol 1982;5:443-447.
33. Löffler TM, Weber FW, Hausamen TU: Five-day continuous infusion mitomycin C: Results of a pilot study. In Taguchi T, Aigner KR (eds): "Mitomycin C in cancer chemotherapy today." Tokyo: Excerpta Medica: 1991. p. 119-123.
34. Johnson RK, Broome MG, Howard WS, et al: Experimental therapeutic and biochemical studies of anthracenedione derivates. In Rozencweig M, Von Hoff DD, Stauquet MJ (eds): "New anticancer drugs: mitoxantrone and bisantrene". New York: Raven Press; 1983. p. 1-28.
35. Scheithauer W, Clark GM, Moyer MP, Von Hoff DD: New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 1986;46:2703-2708.
36. Hoffman RM: In vitro sensitivity assays in cancer: a review, analysis, and prognosis [Review]. J Clin Lab Anal 1991;5:133-143.
37. Phillips RM, Bibby MC, Double JA: A critical appraisal of the predictive value of in vitro chemosensitivity assays [Review]. J Natl Cancer Inst 1990;82:1457-1468.
38. Smit EF, de Vries EG, Timmer-Bosscha H, et al: In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical data. Int J Cancer 1992;51:72-78.
39. Furukawa T, Kubota T, Watanabe M, et al: Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix. J Surg Oncol 1992;49:86-92.
40. Park JG, Kramer BS, Steinberg SM, et al: Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987;47:5875-5879.
41. Mitsuhashi Y, Inaba M, Sugiyama Y, Kobayashi T: In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve. Cancer 1991;70:2540-2546.
42. Schultheis KH, Pliess M, Gentsch HH, et al: Chemoembolization of liver tumors. In Beger HG, Büchler M, Reisfeld RA, et al. (eds): "Cancer therapy". Berlin: Springer-Verlag; 1989. p. 201-215.
43. Kanematsu T, Furuta T, Takenaka K, et al: A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989;10:98-02.
44. Kelsen DP, Hoffman J, Alcock N, et al: Pharmacokinetics of cisplatin regional hepatic infusions. Am J Clin Oncol 1982;5:173-178.
45. DiFilippo F, Giannarelli D, Citro G, et al: Hyperthermic perfusion with cisplatin: standardization of treatment parameters. Reg Cancer Treat 1989;2:131-136.
46. Link KH, Kuehn W, Aigner KR, Voigt H: In vitro bioassay for testing perfusate toxicity in isolation perfusion for extremity melanoma. In Salmon SE (ed): "Adjuvant therapy of cancer V". Orlando: Grune & Stratton; 1987. p. 679-688.
47. Aigner KR, Müller H, Walther H, Link KH: Drug filtration in high-dose regional chemotherapy. Contr Oncol 1988;29:261-280.
48. Gouyette A, Apchin A, Foka M, Richard JM: Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol 1986;22:257-263.
49. Hecquet B, Vennin P, Fournier C, Poissonnier B: Evaluation of the pharmacological benefit and determination of the influencing factors of intraarterial cis-diamminedichloroplatinum administration in patients with uterine cervical cancer. Cancer Res 1987;47:6134-6137.
50. Jacobs SC: Intracavitary hyperthermia and intra-arterial chemotherapy. In Howell SB (ed): "Intra-arterial and intracavitary cancer chemotherapy." Boston: Martinus Nijhoff; 1984. p. 271-281.
51. Loos U, Musch E, Rauschecker H: Kinetics of melphalan in hyperthermic isolation perfusion of the limbs. In Kreidler J, Link KH, Aigner KR (eds): "Advances in regional cancer therapy". Basel: Karger; 1988 p. 221-226.
52. Aigner KR, Link KH, Stemmler S, Warthona M: [Intra-arterial infusion, infusion, experimental and pharmacokinetic basis clinical application]. Beitr Onkol 1985;21:84-107. (Ger).
53. Aigner KR, Walther H, Link KH: Isolated liver perfusion with MMC/ 5-FU - surgical technique, pharmacokinetics, clinical results. Contr Oncol 1988;29:229-246.
54. Aigner KR, Helling HJ, Link KH: [Cytostatic drug filtration during regional chemotherapy]. Beitr Onkol 1985;21:229-245. (Ger).
55. Nagel JD, Krüger I, Ghussen F, Bode U: Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. Cancer Chemother Pharmacol 1991;29:155-158.
56. Aigner KR: [Introductory methods for optimizing the concentrations and time factors in regional chemotherapy]. In Seeber S, Aigner KR, Enghofer E (eds): "Die Lokoregionale Tumortherapie" ["Locoregional tumor therapy"]. Berlin: Walter de Gruyter; 1988 p. 81-93. (Ger).
57. Aigner KR, Walther H, Helling HJ, Link KH: Die isolierte Leberperfusion [Isolated liver perfusion]. Beitr Onkol 1985;21:43-83. (Ger).
58. th American Association of Cancer Research (AACR) conference: 20-24 April 1996; Washington, DC. AACR: Washington, DC: 1996;36:1170.
59. Pillasch J, Link KH, Görich J, et al: Intraarterial chemotherapy for nonresectable liver cancer: effectivity and toxicity of hepatic intraarterial infusion, chemoembolization and the combined modality. Reg Cancer Treat 1995;8:160-165.
60. Link KH, Kindler D, Hummel M, Büchler M: Dose response treatment studies with two pancreatic carcinoma cell lines in vitro [Abstract]. Digestion 1992;52:102.
61. Link KH, Gansauge F, Pillasch J, et al: Regional treatment of advanced nonresectable and of resected pancreatic cancer via celiac axis infusion. First results of a single institution study. Dig Surg 1994;11:414-419.
62. Link KH, Gansauge F, Görich J, et al: Palliative and adjuvant regional chemotherapy in pancreatic cancer. Eur J Surg Oncol. 1997;23:409-414.
63. Alberts DS, Young L, Mason N, Salmon SE: In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol 1985;12(3 Suppl 4):38-42.
64. Kanematsu T, Matsumata T, Furuta T, et al: Lipiodol drug targeting in the treatment of primary hepatocellular carcinoma. Hepatogastroenterology 1990;37:442-444.
65. Naito K, Hisazumi H, Mihara S, et al: Chemosensitivity study of urological malignancies using a novel dye-exclusion method. Cancer Chemother Pharmacol 1987;20 Suppl:S1-S5.
66. Sondak VK, Wong J, Lazar GS, et al: Cytosine arabinoside and cisplatin isolation perfusion for the treatment of malignant melanoma: clinical validation of an in vitro observation. Reg Cancer Treat 1989;2:125-130.
67. Von Hoff DD, Clark GM, Weiss GR, et al: Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 1986;4:1827-1834.
68. Link KH, Kornmann M, Leder GH, et al: Regional chemotherapy directed by individual chemosensitivity testing in vitro: a prospective decision-aiding trial. Clin Cancer Res 1996;2:1469-1474.
69. Arai Y, Kido C, Ariyoshi Y: Phase II study of weekly high dose 5-FU HAI for liver metastases from colorectal cancer [Abstract]. Reg Cancer Treat 1993;6(Suppl 1):4.